Brief: Xvivo Perfusion: Positive Findings In PrimECC Study
May 14 (Reuters) - XVIVO PERFUSION AB XVIVO.ST :
* POSITIVE FINDINGS IN THE PRIMECC STUDY
* STUDY RESULTS ARE PLANNED TO GENERATE FOUR SCIENTIFIC
ARTICLES
* ANALYSIS OF RESULTS SHOWS THAT PRODUCT IS SAFE AND
INDICATES
INTERESTING FINDINGS REGARDING DECREASED SIDE EFFECTS WHEN USING
PRIMECC
Source text for Eikon: ID:nWkr8M1WyR
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength